WITNESS software leads to success for Sanofi
Sanofi aventis has finished implementing Lanner's process simulation software into one of its major UK sites following a successful Phase I implementation in which the company made more than £1 million in inventory cost savings in 6 months.
Sanofi aventis has finished implementing Lanner's process simulation software into one of its major UK sites following a successful Phase I implementation in which the company made more than £1 million in inventory cost savings in 6 months.
The simulation software, WITNESS, enables companies to simulate business decisions and to understand any process. According to Lanner, the software has been used in a variety of sectors including pharmaceutical, energy, nuclear and criminal justice.
In a press statement, Trevor Norman, Continuous Improvement Manager at sanofi-aventis, said: "With the help of Lanner, we simulated a virtual model of our production lines with the new production methods accounted for, and provided us with the data we needed to maximize production efficiency, which in turn reduced our inventory by a massive £1.4 million (1.6 million euro) in the first 6 months alone."
Speaking exclusively to Pharmaceutical Technology Europe, David Jones, CEO of Lanner, explained: "In today's fast-paced environments, organizations require solutions that are easy to use and facilitate a fast return on their investment to drive efficiency gains and streamline their business processes. To help achieve this, organizations are increasingly turning to process simulation technology. Through mapping out business process change in a virtual environment, organizations can ascertain the most effective approach, de-risk decisions and drive down costs while boosting productivity."
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
